GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA (GEC)

Clinical trials for GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA (GEC) explained in plain language.

Never miss a new study

Get alerted when new GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA (GEC) trials appear

Sign up with your email to follow new studies for GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA (GEC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

First look: new cancer drug tested in china for Tough-to-Treat tumors

Disease control Ongoing

This early-stage study aims to check the safety and understand how the body processes the drug tucatinib in a small group of Chinese patients. It includes people with advanced breast, stomach, or colorectal cancers that have a specific marker called HER2+ and have stopped respond…

Matched conditions: GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA (GEC)

Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control

Last updated Mar 30, 2026 14:35 UTC

GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA (GEC)

Get alerted when new GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA (GEC) trials appear

First look: new cancer drug tested in china for Tough-to-Treat tumors